RxDoctor Payments Data

Pablo Olmedo, MD

Family Medicine · Edinburg, TXNPI 1609057074

Payments from drug & device makers

$1,546in general payments, 2019–2025

Across 60 payments — averaging $25.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$442
  • Lilly USA, LLC$303
  • Novo Nordisk$218
  • AstraZeneca$204
  • Amgen$139
  • Ascensia Diabetes Care US Inc.$90
  • plus $151 from 5 others

What the payments were for

  • Food & beverage$1,08770%
  • Education$45930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,546 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$46,719
Medicare patients
113
Services billed
698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin189$198,660
RybelsusSemaglutide130$184,399
OzempicSemaglutide107$136,770
JanuviaSitagliptin Phosphate106$109,727
MyrbetriqMirabegron87$60,966
FarxigaDapagliflozin Propanediol68$60,049
TrulicityDulaglutide37$48,150
JanumetSitagliptin Phos/Metformin Hcl45$46,780
XifaxanRifaximin14$36,107
EliquisApixaban27$27,507
VascepaIcosapent Ethyl54$26,590
MounjaroTirzepatide19$21,233
Tresiba Flextouch U-200Insulin Degludec22$11,487
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,854
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$9,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$218$321,169237 claims
Boehringer IngelheimJardiance$24$198,660189 claims
AstraZenecaFarxiga, Breztri Aerosphere$204$69,98480 claims
Lilly USA, LLCTrulicity, Mounjaro$303$69,38256 claims
Astellas Pharma US IncMyrbetriq$442$60,96687 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Edinburg

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →